Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma
Explore this paper's citation graph
Summary
The data show that lack of response to induction therapy does not automatically predict poor long-term outcome in myeloma, since a substantial proportion of these patients attain CR after autograft and enjoy extended survival.
- Type
- article
- Published
- 2002-11-01
- Cited by
- 80
- References
- 27
- Access
- Open access
- OpenAlex
- https://openalex.org/W2078115159
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:28685173
Keywords
Medicine, Melphalan, Cyclophosphamide, Chemotherapy, Internal medicine
References
- Total therapy with tandem transplants for newly diagnosed multiple myeloma.
- High-dose melphalan with autologous bone marrow transplantation for multiple myeloma.
- High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial.
- Autologous blood and marrow transplantation in patients 60 years and older.
- Intensive chemotherapy with blood progenitor transplantation for primary resistant multiple myeloma
- Comparison of interferon tolerance after autologous bone marrow or peripheral blood stem cell transplants for myeloma patients who have responded to induction therapy.
- Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system
- High-dose intravenous melphalan for plasma-cell leukaemia and myeloma.
- A randomized trial of maintenance interferon following high‐dose chemotherapy in multiple myeloma: long‐term follow‐up results
- Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment
- Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone
- Sterilisation by hysterectomy.
- Intensive treatment of multiple myeloma and criteria for complete remission.
- Prognostic factors in autologous stem cell transplantation for multiple myeloma: an EBMT Registry Study. European Group for Bone Marrow Transplantation.
- Antitumor activity of thalidomide in refractory multiple myeloma.
- Acute lymphoblastic leukaemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma – a phase I/II feasibility and tolerance study of 17 patients
- Autologous stem cell transplantation for relapsed and primary refractory myeloma
- The role of autologous transplantation in patients with multiple myeloma aged 65 years and over
- A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
- Early myeloablative therapy for multiple myeloma.
Cited by
- Effect of artesunate on inhibiting proliferation and inducing apoptosis of SP2/0 myeloma cells through affecting NFκB p65
- New questions about transplantation in multiple myeloma.
- Cure of multiple myeloma – more hype, less reality
- Combining FDG‐PET/CT with laboratory data yields superior results for prediction of relapse in multiple myeloma *
- Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma.
- Rapidity and quality of response to steroid-based induction therapy, without the addition of novel agents, does not affect post transplant outcomes in multiple myeloma.
- Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma
- Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma
- The current status and future of multiple myeloma in the clinic.
- Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT
- Autologous stem cell transplantation in the elderly including pre- and post-treatment options
- Designing risk-adapted therapy for multiple myeloma: the Mayo perspective.
- The role of complete response in multiple myeloma.
- Impact of failed response to novel agent induction in autologous stem cell transplantation for multiple myeloma
- Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients
- Current status of autologous hematopoietic stem cell transplantation in myeloma
- Collection of peripheral blood stem cells in new patients with myeloma receiving minimal or no prior cytoreductive therapy
- Impact of Pre-transplant Therapy and Depth of Disease Response prior to Autologous Transplantation for Multiple Myeloma
- Lenalidomide in Myeloma
- Bortezomib salvage followed by a phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma
Related papers
- Applicability of autotransplantation in cases of missing upper anterior teeth.
- [Conservative therapy for retinoblastoma--effect of melphalan on in vitro electroretinogram].
- Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma
- Factors influencing the chemosensitization of melphalan by misonidazole.
- Tooth autotransplantation in orthodontic patients.
- Phase III study of intermittent 5-drug regimen (VBCMP) versus intermittent 3-drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis.
- Effect of cobalt‐60 (γ radiation) on multidrug‐resistant multiple myeloma cell lines
- 다발성 골수종에 대한 Vincristine , Melphalan 및 Prednisone ( VMP ) 복합화학요법의 치료 효과